<img src="https://ml.globenewswire.com/Resource/Download/4d5346a4-1003-4dbf-8eb2-3786e2557173?size=2" nborder="0" align="left" hspace="5" vspace="5" title="uMethod_Black - 300w.png" alt="uMETHOD Health"/>Study reports 83.5% improved or held their diagnostic stage in real-world patients with early-stage cognitive impairment and dementiaRALEIGH, N.C., Sept. 17, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- uMETHOD Health, Inc., a healthtech company delivering AI-based clinical decision support service for cognitive impairment in older adults, today announced the publication of a peer-reviewed real-world study documenting favorable outcomes from its RestoreU program. RestoreU delivers repeatable, auditable clinical decision support. The platform combines comprehensive medical knowledge, patient-specific data, and AI-enabled analysis to enable clinicians to identify, prioritize, and address treatable causes of cognitive impairment within existing clinical workflows. Turning Clinical Complexity Into Actionable Care Plans According to the Alzheimer's Association, 7.4 million Americans age 65 and older are living with Alzheimer's/dementia, and health care, long-term care, and hospice costs for people with Alzheimer's and other dementias will reach $409 billion in 2026 — not counting the value of unpaid family caregiving. That national burden ultimately lands in the exam room one patient at a time. Patients in the study averaged 74.6 years of age, 9.0 comorbid conditions, 11.7 medications, and 23 clinically significant drug-drug interactions — more interacting variables than any clinician can reconcile by hand during a routine office visit. Cognitive impairment has multiple treatable causes, including medication effects, metabolic health, nutritional deficiencies, sleep, cardiovascular risk, beta amyloid, and other contributors. RestoreU analyzes a patient's complete longitudinal medical record — diagnoses, medications, lab results, genomics, and lifestyle factors — to generate a personalized, prioritized care plan for the clinician, patient, and caregiver. The platform is aligned with Medicare's cognitive assessment and care planning services, and has been commercially deployed since 2016. Clinicians do not need to manually re-enter decades of patient history into a new interface; RestoreU operates within existing lab, electronic medical record, and workflow processes, reducing friction for providers. Peer-Reviewed Study The study by Zelek, Walker, and Crocker-Sabbagh, "<a href="https://www.globenewswire.com/Tracker?data=fLGaPL_SghNyVKH3C2vcpGFJJnOuLcNd5eOoH2SLQ9pptGcOa9ICMQQ5f5tvGHdhp0xwwjAMHYF8jM5x0_6lSFHBYlKKptK4rfdol5yfWd6pJTS6-9HbjrTojoM1RPQhsSRJ0pD8LOc4m85bFbo7OBhMWvMqOjth_SOUWOXvGHZXizVAnRaUYUWkoptsn7QO5HJQLatIySVwRhfAZL4tA8hPanVe_nEWqpxoPzdnoOiTpzXuHXKi2_lLAsQMKX7kCvzY5cmBSFamxkvIGKM7aQ==" rel="nofollow" target="_blank" title="Real-World Cognitive Stabilization via CDSS-Guided Multidomain Interventions in MCI and Older Adults with Cognitive Concerns">Real-World Cognitive Stabilization via CDSS-Guided Multidomain Interventions in MCI and Older Adults with Cognitive Concerns</a>," has been published in the journal Current Aging Science. The study is a retrospective, nonrandomized implementation-and-outcomes analysis of 345 paired cognitive tests, each comparing a patient with themselves on the same validated instrument at baseline and follow-up, over a mean interval of 14.1 months. It found that 83.5% of patients improved, remained stable, or declined slowly without transitioning into a worse diagnostic stage, while another 1.7% declined more slowly than typical and transitioned into the next diagnostic state. "This is a real-world retrospective study, not a randomized controlled trial. There is no usual-care comparison group, and we're careful not to claim more than the data support," said John Q. Walker, co-founder and Chief Technology Officer of uMETHOD Health and principal inventor of RestoreU. "What the data show is that a systematic, AI-supported, multidomain approach to the treatable contributors of cognitive impairment can be delivered consistently and at scale, inside the workflows clinicians already use — and that the resulting cognitive trajectories we observed were favorable." Behavioral neurologist and Alzheimer’s expert Dr. Marwan Sabbagh remarked, “Clinicians have spent years debating pharmacotherapeutic approaches while the factors we can actually change for these patients — medications, metabolic health, sleep, nutrition, vascular risk — went unaddressed in routine care. What is remarkable here is not just the outcome. It is that the results reflect real-world outcomes, and that the approach is systematic enough for any physician to repeat.” About uMETHOD Health uMETHOD Health, Inc. is a healthtech company based in RTP, North Carolina. Founded by Vik Chandra, Chief Executive Officer, and John Q. Walker, Chief Technology Officer, the company has commercially deployed its AI-based clinical decision support platform since 2016. uMETHOD’s Assistive AI is designed to improve care for individuals with chronic diseases that have multiple underlying treatable causes. Media contact: Alexandra Maduell (alexandram@scalto.com) <img alt="" src='https://ml.globenewswire.com/media/Mzg0OTg1MjYtMmI0Yy00Y2FmLWJlMDMtYTg4YTkzNTA2ODk5LTEzMzYzNDktMjAyNi0wOS0xNy1lbg==/tiny/uMETHOD-Health.png' referrerpolicy='no-referrer-when-downgrade' />

uMETHOD Health Publishes Peer-Reviewed Study Documenting Favorable Cognitive Outcomes for its AI-generated RestoreU Care Plans

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn